History
History
-
Hematopoietic Stem
Cell Transplantation -
Academic
Achievements -
Notable Historical
Milestones (Facilities,
Institutions) - MOU
Hematopoietic Stem Cell Transplantation
1983~2023
-
1997Year
OctoberMonth
Cumulative Number of Hematopoietic Stem Cell Transplants
600example
-
Diagnosis
Acute Lymphoblastic Leukemia
-
Type of Transplant
Sibling Allogeneic Stem Cell Transplant
-
-
2009Year
JuneMonth
Cumulative Number of Hematopoietic Stem Cell Transplants
3,500example
-
Diagnosis
Acute Lymphoblastic Leukemia
-
Type of Transplant
Parent-Child Allogeneic Stem Cell Transplant
-
-
2013Year
JulyMonth
Cumulative Number of Hematopoietic Stem Cell Transplants
5,000example
-
Diagnosis
Acute Lymphoblastic Leukemia
-
Type of Transplant
Sibling Allogeneic Stem Cell Transplant
-
-
2022Year
DecemberMonth
Cumulative Number of Hematopoietic Stem Cell Transplants
10,000example
-
Diagnosis
Multiple Myeloma
-
Type of Transplant
Autologous Stem Cell Transplant
-
Cumulative number of hematopoietic stem cell transplants by year
Academic Achievements
1983~today
-
2023
Advanced Materials published our preclinical results on personalized cancer vaccine therapy in acute myeloid leukemia patients.
HemaSphere published our single-cell analysis results for patients with aplastic anemia undergoing immunosuppressive therapy.
-
2022
The importance of comprehensive geriatric assessment in elderly patients with acute myeloid leukemia and the treatment efficacy of decitabine+venetoclax were published in Blood and Blood Cancer Journal, respectively.
Experimental and Molecular Medicine featured our evaluation of Bortezomib treatment response in multiple myeloma patients through single-cell analysis.
-
2021
Results from two phase III studies on allogeneic transplantation at Catholic Blood Hospital were published in the American Journal Of Hematology, covering a comparison of haploidentical family member transplantation vs. unrelated donor transplantation and the preventive effect of low-dose thymoglobulin in sibling transplantation for chronic graft-vs-host disease.
-
2020
During the COVID-19 pandemic, we maintained normal medical services for severe blood disorders, a first for Korea, published in the British Journal of Haematology.
-
2019
Blood also published our first global research on the effectiveness of the new C5 complement inhibitor Ravulizumab, showing it to be as effective as eculizumab in treating paroxysmal nocturnal hemoglobinuria.
The Lancet Haematology highlighted our work on the effectiveness of Romiplostim in treating resistant aplastic anemia.
The New England Journal of Medicine published our world-first findings on the treatment outcomes using fourth-generation tyrosine kinase inhibitors for chronic myelogenous leukemia that is resistant or intolerant.
-
2016
The prestigious Annals of Oncology published our world-first research on improving treatment outcomes in adult Philadelphia chromosome-positive acute lymphoblastic leukemia through combining imatinib with chemotherapy.
-
2015
Our research on the anti-leukemic effects of the new CXCR4 inhibitor LY2510924 was published in Blood.
-
2012
We achieved successful immune tolerance in kidney transplantation through hematopoietic stem cell transplantation.
Our team successfully completed an allogeneic hematopoietic stem cell transplantation for a thalassemia major patient in Abu Dhabi.
-
2008
We conducted Korea's first T/NK cell therapy.
-
2005
Our groundbreaking work on improving outcomes for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia, using pre-transplant imatinib treatment, was the first to be published in Blood, a leading hematology journal.
-
2002
Globally, we were the first to successfully perform a liver transplantation after an allogeneic hematopoietic stem cell transplantation.
-
2001
We were pioneers in conducting the first successful haploidentical family member transplantation in Korea.
-
2000
We broke new ground with the first successful transplantation for autoimmune diseases in Korea, specifically for Multiple Sclerosis.
-
1998
Our team achieved the first successful non-myeloablative allogeneic hematopoietic stem cell transplantation in Korea.
-
1996
We were the first in Korea to successfully perform an umbilical cord blood transplantation.
-
1995
Another first in Korea was our successful transplantation from a non-related, matched donor.
-
1985
We also led the first successful autologous hematopoietic stem cell transplantation in Korea.
-
1983
In March, we achieved a groundbreaking success in Korea by performing the first successful allogeneic hematopoietic stem cell transplantation on an adult with lymphoblastic leukemia.
Notable Historical Milestones (Facilities, Institutions)
1992~2022
-
2022
Also in March, we restructured to introduce an Hematology Hospitalist Center, which includes 7 specialized centers.
-
2018
In March, Seoul St. Mary's Hospital opened a specialized Hematology Hospital.
-
2005
We began cooperation with a hematopoietic stem cell bank in the United States, extending our reach globally.
We kicked off collaboration with a hematopoietic stem cell bank in Germany, strengthening our international connections.
-
1997
We initiated a partnership with a hematopoietic stem cell bank in Taiwan, representing our efforts in the Asian region.
We started collaborating with a hematopoietic stem cell bank in Japan, further expanding our network in Asia.
-
1994
In December, we expanded and upgraded to become the largest hematopoietic stem cell transplantation center in Asia.
We established Korea's first Catholic Hematopoietic Stem Cell Bank.
-
1992
In May, we launched Korea's first Catholic Bone Marrow Transplant Center.
We became the first in Korea to register with the International Bone Marrow Transplant Registry.
MOU
2018~2022
-
2022
Another business agreement was signed in August, this time with GENOMEinSIGHT Inc.
-
2021
In February, LOKKS307 Inc. became a new business partner.
In March, we also partnered with iKooB Inc.
In August, a business agreement was forged with Eutilex
In December, we teamed up with Imprimed Korea Inc.
-
2018
In March, we entered into a business partnership with the Seocho Symphony Orchestra.
In May, we signed a business agreement with VUNO Inc.
In September, we established a partnership with the Center for Genomic Integrity (CGI), Institute of Basic Science (IBS)